NEW - Palmitoylethanolamide (PEA)

- Categories : News, Studies and Articles

The Oronalys laboratory is delighted to present to you a brand new food supplement based on Palmitoylethanolamide (PEA), with patented OptiPEA® quality. PEA is a product that arouses interest due to its multiple applications for health. Due to its action with several receptors, it has extensive and favorable potential for a global approach to health.

What is the PEA?

Palmitoylethanolamide (PEA) is a naturally occurring compound that dates back hundreds of millions of years through evolution and is found in plant and animal cells. It is an endocannabinoid lipid mediator whose anti-inflammatory, analgesic, antimicrobial, immunomodulatory and neuroprotective effects are widely documented. PEA is an effective solution for the management of chronic and neuropathic pain, an effectiveness proven by more than 700 scientific articles, 60 medical indications for use, and 60 years of research. Unlike CBD, PEA is well tolerated by the body and has no side effects.

OptiPEA® quality: 99% purity

Rita Levi Montalcini, Nobel Prize winner in medicine, observed that PEA acts on both the central nervous system and the peripheral nervous system. She identified the complex mechanisms of action, highlighting the activity of PEA in reducing tissue inflammation and mast cell degranulation in vivo, reducing the hyperalgesia that accompanies peripheral nerve compression. PEA's actions on multiple molecular targets while modulating multiple inflammatory mediators provide therapeutic benefits in numerous applications including immunity, brain health, allergies, pain modulation, joint health, sleep and recovery.

Besides chronic pain syndromes and chronic inflammation, there are dozens of other medical indications for use.These include: headaches (migraines and occipital neuralgia), pain and inflammation (endometriosis...), neurodegenerative disorders (Alzheimer's and ALS), mood disorders (depression and anxiety), autoimmune diseases (MS and fibromyalgia) and infections (flu and colds).

OptiPEA®: scientifically proven effectiveness

A randomized, placebo-controlled, double-blind crossover trial demonstrated that OptiPEA® has clinically relevant analgesic properties, acting on both peripheral and central mechanisms as well as pain modulation. This trial was carried out with a dose of 3x 400mg per day of OptiPEA®.

Lang-Illievich K, Klivinyi C, Rumpold-Seitlinger G, Dorn C, Bornemann-Cimenti H. The Effect of Palmitoylethanolamide on Pain Intensity, Central and Peripheral Sensitization, and Pain Modulation in Healthy Volunteers—A Randomized, Double-Blinded, Placebo- Controlled Crossover Trial.  Nutrients. 2022; 14(19):4084. https://doi.org/10.3390/nu14194084

PEA 400mg (Ref. 089.1), 30 capsules, 25€

PEA 400mg (Ref. 089.2), 90 capsules, 59€

Ingredients per capsule: Palmitoylethanolamide (PEA) - OptiPEA®, 400mg

Dosage: 3 capsules per day

We recommend that you do not exceed the recommended daily dose and follow the recommendations of your healthcare professional.

Share this content